The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Combiprasal 0.5 mg / 2.5 mg per 2.5 ml nebuliser solution

0.5 mg/2.5 milligram(s) Nebuliser solution

Pharma Stulln GmbHPA1815/001/001

Main Information

Trade NameCombiprasal 0.5 mg / 2.5 mg per 2.5 ml nebuliser solution
Active SubstancesIpratropium bromide
SALBUTAMOL SULFATE
Strength0.5 mg/2.5 milligram(s)
Dosage FormNebuliser solution
Licence HolderPharma Stulln GmbH
Licence NumberPA1815/001/001

Group Information

ATC CodeR03AL Adrenergics in combination with anticholinergics
R03AL02 salbutamol and ipratropium bromide

Status

Authorised/WithdrawnAuthorised
Licence Issued10/01/2014
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0081-136-052
Interchangeable List DocumentPDF of Interchangeable List
« Back